

Hongyong He

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1135169/publications.pdf>

Version: 2024-02-01

40
papers

1,035
citations

516710

16
h-index

477307

29
g-index

41
all docs

41
docs citations

41
times ranked

1257
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer. <i>Gut</i> , 2019, 68, 1764-1773.	12.1	219
2	Morbidity and Mortality of Laparoscopic vs Open Total Gastrectomy for Clinical Stage I Gastric Cancer. <i>JAMA Oncology</i> , 2020, 6, 1590.	7.1	128
3	Poor Clinical Outcomes and Immuno-evasive Contexture in Intratumoral IL-10-Producing Macrophages Enriched Gastric Cancer Patients. <i>Annals of Surgery</i> , 2022, 275, e626-e635.	4.2	95
4	CXCL13 expression is prognostic and predictive for postoperative adjuvant chemotherapy benefit in patients with gastric cancer. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 261-269.	4.2	43
5	Snail is an independent prognostic predictor for progression and patient survival of gastric cancer. <i>Cancer Science</i> , 2012, 103, 1296-1303.	3.9	38
6	Tumor-infiltrating $\beta 1 T$ cells predict prognosis and adjuvant chemotherapeutic benefit in patients with gastric cancer. <i>Oncolmunology</i> , 2017, 6, e1353858.	4.6	38
7	Identification and validation of an immunogenic subtype of gastric cancer with abundant intratumoural CD103+CD8+ T cells conferring favourable prognosis. <i>British Journal of Cancer</i> , 2020, 122, 1525-1534.	6.4	34
8	Intratumoral CXCR5+CD8+T associates with favorable clinical outcomes and immunogenic contexture in gastric cancer. <i>Nature Communications</i> , 2021, 12, 3080.	12.8	34
9	CD47 expression in gastric cancer clinical correlates and association with macrophage infiltration. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1831-1840.	4.2	32
10	Upregulated Expression of C-X-C Chemokine Receptor 4 Is an Independent Prognostic Predictor for Patients with Gastric Cancer. <i>PLoS ONE</i> , 2013, 8, e71864.	2.5	31
11	Poor clinical outcomes of intratumoral dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin-positive macrophages associated with immune evasion in gastric cancer. <i>European Journal of Cancer</i> , 2020, 128, 27-37.	2.8	28
12	Survival benefit of greater number of lymph nodes dissection for advanced node-negative gastric cancer patients following radical gastrectomy. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 63-70.	1.3	22
13	Association of O ⁶ -Methylguanine-DNA Methyltransferase Protein Expression With Postoperative Prognosis and Adjuvant Chemotherapeutic Benefits Among Patients With Stage II or III Gastric Cancer. <i>JAMA Surgery</i> , 2017, 152, e173120.	4.3	22
14	Interleukin-13 receptor $\beta 2$ is associated with poor prognosis in patients with gastric cancer after gastrectomy. <i>Oncotarget</i> , 2016, 7, 49281-49288.	1.8	20
15	Study on safety of laparoscopic total gastrectomy for clinical stage I gastric cancer: the protocol of the CLASS02-01 multicenter randomized controlled clinical trial. <i>BMC Cancer</i> , 2018, 18, 944.	2.6	19
16	Poor clinical outcomes and immuno-evasive contexture in CXCL13+CD8+ T cells enriched gastric cancer patients. <i>Oncolmunology</i> , 2021, 10, 1915560.	4.6	17
17	Latency-associated Peptide Identifies Immuno-evasive Subtype Gastric Cancer With Poor Prognosis and Inferior Chemotherapeutic Responsiveness. <i>Annals of Surgery</i> , 2022, 275, e163-e173.	4.2	17
18	C-C motif chemokine 22 predicts postoperative prognosis and adjuvant chemotherapeutic benefits in patients with stage II/III gastric cancer. <i>Oncolmunology</i> , 2018, 7, e1433517.	4.6	16

#	ARTICLE	IF	CITATIONS
19	Lauren classification identifies distinct prognostic value and functional status of intratumoral CD8+ T cells in gastric cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1327-1336.	4.2	16
20	Clinical Outcomes and Immune Metrics in Intratumoral Basophil-Enriched Gastric Cancer Patients. <i>Annals of Surgical Oncology</i> , 2021, 28, 6439-6450.	1.5	16
21	Galectin-8 is associated with recurrence and survival of patients with non-metastatic gastric cancer after surgery. <i>Tumor Biology</i> , 2016, 37, 12635-12642.	1.8	15
22	Lymphocyte activation gene 3 expression associates with poor prognosis and immunoevasive contexture in Epstein-Barr virus positive and MLH1 defective gastric cancer patients. <i>International Journal of Cancer</i> , 2021, 148, 759-768.	5.1	15
23	Impact of intratumoural CD73 expression on prognosis and therapeutic response in patients with gastric cancer. <i>European Journal of Cancer</i> , 2021, 157, 114-123.	2.8	15
24	Intratumoral CD103 ⁺ CD4 ⁺ T cell infiltration defines immunoevasive contexture and poor clinical outcomes in gastric cancer patients. <i>Oncolmmunology</i> , 2020, 9, 1844402.	4.6	14
25	Immune inactivation by APOBEC3B enrichment predicts response to chemotherapy and survival in gastric cancer. <i>Oncolmmunology</i> , 2021, 10, 1975386.	4.6	14
26	TIM3+ cells in gastric cancer: clinical correlates and association with immune context. <i>British Journal of Cancer</i> , 2022, 126, 100-108.	6.4	12
27	Intratumoral IL-1R1 expression delineates a distinctive molecular subset with therapeutic resistance in patients with gastric cancer. , 2022, 10, e004047.		12
28	CXC chemokine receptor 1 predicts postoperative prognosis and chemotherapeutic benefits for TNM II and III resectable gastric cancer patients. <i>Oncotarget</i> , 2017, 8, 20328-20339.	1.8	10
29	Intratumoral Foxp3 ⁺ RORγt ⁺ T cell infiltration determines poor prognosis and immunoevasive contexture in gastric cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1-11.	4.2	9
30	Intratumoral interleukin-9 delineates a distinct immunogenic class of gastric cancer patients with better prognosis and adjuvant chemotherapeutic response. <i>Oncolmmunology</i> , 2020, 9, 1856468.	4.6	8
31	Tumor-infiltrating podoplanin ⁺ cells in gastric cancer: clinical outcomes and association with immune contexture. <i>Oncolmmunology</i> , 2020, 9, 1845038.	4.6	7
32	Tumor size and perineural invasion predict outcome of gastric high-grade neuroendocrine neoplasms. <i>Endocrine Connections</i> , 2021, 10, 947-954.	1.9	6
33	Glycoprotein 130 is associated with adverse postoperative clinical outcomes of patients with late-stage non-metastatic gastric cancer. <i>Scientific Reports</i> , 2016, 6, 38364.	3.3	4
34	Single Purse-String Suture for Reinforcement of Duodenal Stump During Laparoscopic Radical Gastrectomy for Gastric Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1020.	2.8	3
35	Decreased expression of granulocyte-macrophage colony-stimulating factor is associated with adverse clinical outcome in patients with gastric cancer undergoing gastrectomy. <i>Oncology Letters</i> , 2017, 14, 4701-4707.	1.8	2
36	OUP accepted manuscript. <i>Gastroenterology Report</i> , 2022, 10, goab054.	1.3	2

#	ARTICLE	IF	CITATIONS
37	ASO Author Reflections: Optimization of Tumor Therapy for the Specific Immune Microenvironment of Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 6451-6452.	1.5	1
38	Laparoscopic versus open total gastrectomy for clinical stage I gastric cancer: Morbidity and mortality results from a prospective randomized multicenter controlled trial (CLASS02).. <i>Journal of Clinical Oncology</i> , 2020, 38, 378-378.	1.6	1
39	Alcohol consumption adjusted by aldehyde dehydrogenase 2 genotype: A potential risk factor for gastric cancer?. <i>Journal of Clinical Oncology</i> , 2017, 35, e15541-e15541.	1.6	0
40	Risk factors associated with early postoperative complications following laparoscopic total gastrectomy: Experience from the Chinese Laparoscopic Gastrointestinal Surgery Study (CLASS) group.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15544-e15544.	1.6	0